Johnson & Johnson Overview
Johnson & Johnson Inc engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company's segments include consumer, pharmaceutical, and medical devices. The company's primary focus is on products related to human health and wellbeing. In Israel, Johnson & Johnson has four sub-companies. The company's operations in Israel span research and development, as well as commercial activities in the healthcare sector.
Latest News
growth-positive
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from Johnson & Johnson and other med-tech firms. Sivan Matza joins the board as an independent director, leveraging her background in global finance and regulation. These appointments aim to enhance Inspiras sales strategy and hospital adoption initiatives, positioning the company for its next phase of growth. The company also acknowledged the contributions of Limor Rosen, who is stepping down from the board.
Management Changes
growth-positive
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from the healthcare sector, including roles at Johnson & Johnson. Sivan Matza joins the board as an independent director, succeeding Limor Rosen. Matzas background in international finance and regulation is expected to enhance Inspiras governance framework. These appointments are strategic moves to accelerate Inspiras commercial expansion and adoption of its technologies in hospitals worldwide. The company expressed gratitude to Limor Rosen for her contributions.
Management Changes
growth-positive
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Johnson & Johnson (J&J) discussed its optimistic outlook for 2026 during its third-quarter earnings call on October 14. The company expects top-line growth of over 5%, surpassing the consensus estimate of 4.6%. J&J anticipates similar growth in EPS, projecting it to be 5 cents higher than the consensus of $11.39 per share. Despite the loss of exclusivity for Stelara, J&J expects growth in its Innovative Medicine and MedTech segments, driven by key products and new launches. The MedTech segment is expected to benefit from increased adoption of new products and a focus on high-growth markets. J&Js guidance reflects a strategic shift towards innovation-led growth.
growth-positive
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
Johnson & Johnson reported strong third-quarter 2025 earnings, with earnings per share of $2.80, surpassing the Zacks Consensus Estimate of $2.77. This marks a 15.7% increase from the previous year. The companys sales reached $24.0 billion, exceeding expectations and reflecting a 6.8% rise from the prior year. The growth was driven by increased sales in the Innovative Medicines segment, particularly from key products like Darzalex, Tremfya, and Erleada. Despite some challenges from generic competition affecting drugs like Imbruvica, the overall performance was robust. The companys international sales also showed significant growth, contributing to the positive outlook.
growth-positive
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Johnson & Johnson is set to report its third-quarter 2025 earnings on October 14, with expectations of a positive earnings surprise. The companys performance has been strong, consistently exceeding earnings expectations over the past four quarters. Key products such as Darzalex, Tremfya, and Erleada are expected to drive sales growth, while new drugs like Carvykti and Tecvayli are contributing to top-line growth. However, the Innovative Medicines segment faces challenges due to the launch of biosimilar versions of Stelara, impacting growth negatively. Despite this, the overall outlook remains positive, with a projected earnings beat.
Team Members
2
Employees: 201-500
Web & Social Links
| Website | www.jnj.com/ |
Locations
Shefayim, Israel
Yokne'am Illit, Israel
New Jersey, USA
Photos & Videos
No files yet
Johnson & Johnson Business
Business models
—
Product stage
—
Employees
201-500
Sector
—Target Customer
—Core Technology
—Tags (6)
digital-healthcarepharmaceuticalsbiopharmaceuticaltherapeuticsbiotechnologysupply-chainJohnson & Johnson Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Johnson & Johnson Lifecycle
Johnson & Johnson News
23 articles
growth-positive
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from Johnson & Johnson and other med-tech firms. Sivan Matza joins the board as an independent director, leveraging her background in global finance and regulation. These appointments aim to enhance Inspiras sales strategy and hospital adoption initiatives, positioning the company for its next phase of growth. The company also acknowledged the contributions of Limor Rosen, who is stepping down from the board.
Management Changes
growth-positive
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from the healthcare sector, including roles at Johnson & Johnson. Sivan Matza joins the board as an independent director, succeeding Limor Rosen. Matzas background in international finance and regulation is expected to enhance Inspiras governance framework. These appointments are strategic moves to accelerate Inspiras commercial expansion and adoption of its technologies in hospitals worldwide. The company expressed gratitude to Limor Rosen for her contributions.
Management Changes
growth-positive
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Johnson & Johnson (J&J) discussed its optimistic outlook for 2026 during its third-quarter earnings call on October 14. The company expects top-line growth of over 5%, surpassing the consensus estimate of 4.6%. J&J anticipates similar growth in EPS, projecting it to be 5 cents higher than the consensus of $11.39 per share. Despite the loss of exclusivity for Stelara, J&J expects growth in its Innovative Medicine and MedTech segments, driven by key products and new launches. The MedTech segment is expected to benefit from increased adoption of new products and a focus on high-growth markets. J&Js guidance reflects a strategic shift towards innovation-led growth.
growth-positive
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
Johnson & Johnson reported strong third-quarter 2025 earnings, with earnings per share of $2.80, surpassing the Zacks Consensus Estimate of $2.77. This marks a 15.7% increase from the previous year. The companys sales reached $24.0 billion, exceeding expectations and reflecting a 6.8% rise from the prior year. The growth was driven by increased sales in the Innovative Medicines segment, particularly from key products like Darzalex, Tremfya, and Erleada. Despite some challenges from generic competition affecting drugs like Imbruvica, the overall performance was robust. The companys international sales also showed significant growth, contributing to the positive outlook.
growth-positive
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Johnson & Johnson is set to report its third-quarter 2025 earnings on October 14, with expectations of a positive earnings surprise. The companys performance has been strong, consistently exceeding earnings expectations over the past four quarters. Key products such as Darzalex, Tremfya, and Erleada are expected to drive sales growth, while new drugs like Carvykti and Tecvayli are contributing to top-line growth. However, the Innovative Medicines segment faces challenges due to the launch of biosimilar versions of Stelara, impacting growth negatively. Despite this, the overall outlook remains positive, with a projected earnings beat.
growth-positive
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
The U.S. stock market saw a strong performance last week, with major indices showing gains despite a partial government shutdown. Investor optimism was fueled by innovations in Artificial Intelligence and hopes for interest rate cuts by the Federal Reserve. However, the shutdown has caused uncertainties due to delays in economic data releases. The Conference Boards Consumer Confidence Index fell, indicating concerns over inflation and a weakening job market. Amid these conditions, Zacks Research has provided guidance to investors, highlighting the performance of stocks like Amneal Pharmaceuticals, Inc., which gained 29.9% since being upgraded to a Zacks Rank #2. The article underscores the importance of strategic investment decisions in uncertain market conditions.
growth-positive
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Johnson & Johnson (J&J) has experienced a significant stock price increase, with shares up 17.7% over the past three months, adding nearly $63 billion in market capitalization. The companys Innovative Medicine unit is showing growth, with sales rising 2.4% in the first half of 2025. J&J expects continued growth driven by key products and new drugs. The MedTech segment also saw sales growth, driven by acquisitions and new product adoption. J&Js oncology sales are projected to exceed $50 billion by 2030. Recent FDA approvals for drugs like Inlexzo and acquisitions such as Intra-Cellular Therapies are contributing to J&Js positive outlook.
Product StageAcquisitionFDA approved/pending approval
growth-negative
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
Johnson & Johnsons immunology drug, Stelara, lost its patent exclusivity in the United States in 2025, leading to the launch of several biosimilar versions by companies like Amgen, Teva Pharmaceutical Industries/Alvotech, and Samsung Bioepis/Sandoz. This has significantly eroded Stelaras sales, which declined by 42.7% in the second quarter of 2025, impacting J&Js sales and profits. Despite this, J&J anticipates growth in its Innovative Medicine segment, driven by other key products and new drugs. The company expects to generate over $57 billion in sales in this segment in 2025, maintaining levels similar to 2024.
Product StageCustomers
growth-negative
Commentary: Trump’s trade war is hurting most sectors of the economy
The article discusses the negative impact of President Trumps tariffs on various sectors of the US economy, particularly highlighting the effects on companies within the S&P 500 index. It notes that tariffs have significantly increased costs for businesses, leading to reduced profits and price hikes. General Motors, for example, reported a $1.1 billion hit to profits in the second quarter due to tariffs. Other companies like Ford, Home Depot, and Walmart also face similar challenges, with increased costs and reduced profit margins. The article emphasizes the widespread economic damage caused by the tariffs, affecting both businesses and consumers.
Customers
growth-positive
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson (J&J) has been experiencing a positive stock performance, with its stock trading above the 50-day and 200-day simple moving averages since mid-June 2025. This bullish trend, known as a golden cross, suggests potential for continued upward momentum. J&Js strengths lie in its diversified business model, operating in both medical devices and pharmaceuticals. The company separated its Consumer Health business into Kenvue, allowing it to focus on core areas. Despite challenges like the loss of exclusivity for Stelara, J&Js Innovative Medicine unit is showing growth, with expectations of significant sales in 2025 and beyond. The company anticipates oncology sales to exceed $50 billion by 2030.
growth-positive
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
growth-positive
US-EU trade deal impacts on pharma industry more 'manageable' than expected
The recent trade deal between the US and the EU, which sets a 15% cap on import tariffs for pharmaceutical goods, has been positively received by the pharmaceutical industry. Stocks of major pharmaceutical companies like Pfizer, Eli Lilly, and Johnson & Johnson saw a slight increase following the announcement. The deal aims to equalize US drug costs with those in the EU by applying the higher of either the US MFN tariff rate or a 15% tariff on EU-manufactured drugs. Additionally, the US will enforce MFN pricing on generics and chemical precursors starting September 1. This is seen as a manageable change, with limited financial impact on the industry.
growth-negative
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Teva Pharmaceutical Industries reported second-quarter 2025 adjusted earnings of 66 cents per share, surpassing the Zacks Consensus Estimate of 63 cents. However, revenues of $4.18 billion missed the estimate of $4.28 billion, remaining flat year over year. The revenue growth was hindered by lower generic drug sales, despite increased sales of branded drugs like Austedo, Ajovy, and Uzedy. Tevas exit from Japan contributed to the decline in generic sales. The company launched new biosimilars, Simlandi and Selarsdi, in partnership with Alvotech, and Epysqli with Samsung Bioepis. Despite these efforts, Tevas shares have decreased by 23.6% this year, compared to the industrys 9.8% decline.
Product StagePartnersCustomers
growth-positive
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Johnson & Johnson (J&J) reported strong second-quarter 2025 results, surpassing expectations in both revenue and earnings. Despite the loss of exclusivity for Stelara, J&Js Innovative Medicines unit and MedTech segment performed well, driven by strong sales of key drugs and new products. The company raised its sales and EPS guidance for the year, reflecting strong operational performance and favorable currency impacts. J&Js shares rose over 6% following the earnings announcement. The companys diversified business model, with operations in both medical devices and pharmaceuticals, continues to be a significant strength. In 2023, J&J separated its Consumer Health business into a new company, Kenvue, allowing it to focus on its core areas.
growth-positive
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited has seen a 21.6% rise in its stock price over the past three months, driven by the successful launch of several biosimilars and high-value generics. The companys branded drugs, including Austedo, Uzedy, and Ajovy, are experiencing strong sales growth. Teva has implemented cost-cutting measures to improve operating profits and reduce debt. The company anticipates significant revenue growth from its branded products by 2030, with Austedo expected to generate over $2.5 billion annually by 2027. Teva has partnered with Sanofi to advance its anti-TL1A therapy, duvakitug, into phase III trials. The company continues to expand its market presence with new launches in Europe and international markets.
Product StagePartnersCustomers
growth-positive
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
Johnson & Johnson (J&J) has seen a 4.4% rise in its stock over six months, adding over $15 billion to its market value. Despite challenges like slowing MedTech sales, loss of exclusivity for Stelara, and talc lawsuits, J&Js strengths lie in its diversified business model and strong Innovative Medicine unit. The company has separated its Consumer Health business into Kenvue, allowing it to focus on pharmaceuticals and medical devices. J&J anticipates significant growth in its Innovative Medicine segment, driven by key products and new drug launches, with expectations of over $57 billion in sales by 2025.
Product StageAcquired-by
growth-positive
Pharma giant adds Israel to list of Middle East markets after omission raises questions
Johnson & Johnson has added Israel to its list of global markets on its order management website, Customer Connect, after questions were raised about its absence. The website is a tool for the companys direct customers and distributors in North America, Latin America, Europe, Middle East, Africa, and Asia Pacific. The company clarified that the tool isnt used for all markets, and customers in markets not listed, including Israel, use a different method to order products. The company also condemned the Oct. 7 Hamas terrorist attack on Israel and donated $2 million to support humanitarian relief.
Customers
growth-positive
Bank Bonds That Cut Risk Draw Ares and Blackstone: Credit Weekly
Banks are reviving the sale of credit-linked notes, a type of synthetic securitization, ahead of new rules that will require them to hold more regulatory capital. The bonds are used by lenders to reduce the financial resources they have to retain against loans on their balance sheet. The revival comes as banks wait to hear the latest terms of forthcoming Basel III regulations. Analysts at JPMorgan Chase & Co. see the mortgage-related CLN market alone growing to about $60 billion in the US in five years time. Magnetar Capital and Ares Management Corp. are also buying the bonds, which can yield anything from high single digits to mid-double digits, depending on the underlying collateral.
InvestmentPartners
J&J Weighs Third Bankruptcy Try to Settle Baby Powder Suits
growth-negative
J&J to close Tel Hashomer blood bank operations
Johnson & Johnson is closing down its blood bank at Sheba Medical Center in Israel, which it acquired through Omrix Biopharmaceuticals. The facility will operate on a limited format until 2021, when it will be shut down completely. This follows the closure of Johnson & Johnsons plant in Jerusalem last year. 100 employees will be laid off as a result of the blood bank closure. Johnson & Johnson acquired Omrix in 2008 for $348 million. The company develops blood plasma-based products for surgery. The state of Israel previously filed a lawsuit against Johnson & Johnson regarding intellectual property, which was settled in 2006. Johnson & Johnson is still active in Israel through its subsidiary Biosense Webster.
Layoffs
growth-positive
J&J leads $28m round in Israel's V-Wave
Israeli startup V-Wave has raised $28 million in a funding round led by Johnson & Johnson Innovation - JJDC Inc., with participation from TriVentures, Pura Vida, BioStar Ventures, Eli and Nir Barkats BRM fund, Pontifax and Edwards Lifesciences. The funds will be used to support clinical evaluation and development, addition of senior management and manufacturing scale-up of V-Waves proprietary minimally invasive device for use in patients with chronic symptomatic heart failure. The company has already successfully implanted the device in 30 patients.
InvestmentManagement ChangesExpand
growth-positive
Johnson & Johnson to establish new biotechnology incubator in Israel
Johnson & Johnson Innovation is expanding its global incubator presence in Israel with a new biotechnology incubator. The company is collaborating with the Office of the Chief Scientist in Israel and other industry partners to set up the research and development center. The new incubator aims to support and advance new companies with funding and strategic advice. Partners involved in the project include Johnson & Johnson Development Corporation, Takeda Pharmaceutical, and OrbiMed Israel Partners. Johnson & Johnson Innovation has been announcing several new R&D collaborations worldwide to fuel entrepreneurship. The new Israeli incubator is expected to be operational in early 2014.
PartnersInvestment
growth-positive
Omrix obtains FDA approval for fibrin sealant
Omrix, a Johnson & Johnson unit, has obtained FDA approval for its fibrin human sealant patch, now called Evarrest. The sealant is used to stop bleeding during surgery and is 98% effective in maintaining hemostasis. Omrix will produce Evarrest in Israel. The FDA approval is good news for Johnson & Johnson and for Israels life sciences industry. Omrix is also in talks with Octapharma AG for other production options. The company is currently involved in a lawsuit with the State of Israel regarding royalties on the acquisition of intellectual property. The case is still pending.
Customers
Johnson & Johnson Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 314 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Johnson & Johnson Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:21:40.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:45:24.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:17:27.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-18 18:56:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:17:26.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 13:49:35.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-17 13:19:01.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:17:26.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-18 18:59:53.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:17:37.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:19:55.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-18 18:59:53.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-03-14 19:44:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-08-09 13:17:27.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-18 18:56:19.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 09:10:55.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 09:10:55.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 08:56:40.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 08:56:40.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 09:23:26.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-26 08:45:30.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2017-11-09 13:02:51.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2017-11-09 13:02:51.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 68/100 |
| Missing | product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Crunchbase | johnson-johnson |
| Creator | Yamila Silbert |
| Creator email | yamila.urwicz@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2024-07-17T00:00:00.000Z |
| Created | 2016-06-01T00:00:00.000Z |
| Status detail | Public on NYSE on Jan, 1978; |